Interplay of salicylaldehyde, lysine, and M 2+ ions on α-synuclein aggregation: Cancellation of aggregation effects and determination of salicylaldehyde neurotoxicity

Neuroscience Research

Volumn 71, Issue 2, 2011, Pages 168-177

  Ha, Yonghwang ^a,b   Liew, Hyunjeong ^c   Park, Hyun Young ^a   Kim, Kibong ^a   Suh, Yoo Hun ^c   Churchill, David G ^a  

^a Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^b Jungwon University   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

Synuclein; Copper(II); L Lysine; Protein aggregation; Salicylaldehyde; Zinc(II)

Indexed keywords

ALPHA SYNUCLEIN; COPPER ION; LYSINE; MANGANESE; SALICYLALDEHYDE; SCAVENGER; ZINC ION;

ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; FLUORESCENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INCUBATION TEMPERATURE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NEUROTOXICITY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; SCAVENGING SYSTEM;

ALDEHYDES; ALPHA-SYNUCLEIN; CELL LINE, TUMOR; CELL SURVIVAL; COPPER; HUMANS; LYSINE; MANGANESE; NEURONS; PROTEIN BINDING; ZINC;

EID: 80052385533     PISSN: 01680102     EISSN: 18728111     Source Type: Journal    
DOI: 10.1016/j.neures.2011.07.003     Document Type: Article

References (49)

1. Aalto-Korte K., Valimaa J., Henriks-Eckerman M.L., Jolanki R. Allergic contact dermatitis from salicyl alcohol and salicylaldehyde in aspen bark (Populus tremula). Contact Dermatitis 2005, 52(2):93-95.
2. Alimonti A., Bocca B., Pino A., Ruggieri F., Forte G., Sancesario G. Elemental profile of cerebrospinal fluid in patients with Parkinson's disease. J. Trace Elem. Med. Biol. 2007, 21(4):234-241.
3. Banks W.A. Characteristics of compounds that cross the blood-brain barrier. BMC Neurol. 2009, 9.
4. Beyer K. A-synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers. Acta Neuropathol. 2006, 112(1):237-251.
5. Bieschke J., Zhang Q., Bosco D.A., Lerner R.A., Powers E.T., Wentworth P., Kelly J.W. Small molecule oxidation products trigger disease-associated protein misfolding. Acc. Chem. Res. 2006, 39(9):611-619.
6. Bosco D.A., Fowler D.M., Zhang Q., Nieva J., Powers E.T., Wentworth P., Lerner R.A., Kelly J.W. Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate [alpha]-synuclein fibrilization. Nat. Chem. Biol. 2006, 2(5):249-253.
7. Burke W.J., Chung H.D., Li S.W. Quantitation of 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde, the monoamine oxidase metabolites of dopamine and noradrenaline, in human tissues by microcolumn high-performance liquid chromatography. Anal. Biochem. 1999, 273(1):111-116.
8. Burke W.J., Kumar V.B., Pandey N., Panneton W.M., Gan Q., Franko M.W., O'Dell M., Li S.W., Pan Y., Chung H.D., Galvin J.E. Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine. Acta Neuropathol. (Berl.) 2008, 115(2):193-203.
9. Burke W.J., Li S.W., Williams E.A., Nonneman R., Zahm D.S. 3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis. Brain Res. 2003, 989(2):205-213.
10. Bush A.I. The metallobiology of Alzheimer's disease. Trends Neurosci. 2003, 26(4):207-214.
11. Cole N.B., Murphy D.D., Lebowitz J., Di Noto L., Levine R.L., Nussbaum R.L. Metal-catalyzed oxidation of A-synuclein: helping to define the relationship between oligomers, protofibrils, and filaments. J. Biol. Chem. 2005, 280(10):9678-9690.
12. Davidson W.S., Jonas A., Clayton D.F., George J.M. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 1998, 273(16):9443-9449.
13. Fraústo da Silva J.J.R., Williams R.J.P. The Biological Chemistry of the Elements: The Inorganic Chemistry 1993, Oxford University Press Inc., New York, pp. 71-94.
14. Gellein K., Garruto R., Syversen T., Sjøbakk T., Flaten T. Concentrations of Cd, Co, Cu, Fe, Mn, Rb, V, and Zn in formalin-fixed brain tissue in amyotrophic lateral sclerosis and parkinsonism-dementia complex of guam determined by high-resolution ICP-MS. Biol. Trace Elem. Res. 2003, 96(1):39-60.
15. Ha Y., Tsay O., Churchill D. A tutorial and mini-review of the ICP-MS technique for determinations of transition metal ion and main group element concentration in the neurodegenerative and brain sciences. Monatshefte für Chemie/Chem. Monthly 2011, 142(4):385-398.
16. Janeš D., Kreft S. Salicylaldehyde is a characteristic aroma component of buckwheat groats. Food Chem. 2007, 109:293-298.
17. Jeffrey D.R. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann. Neurol. 2009, 65(S1):S3-S9.
18. Jeong M.S., Kang J.H. Acrolein, the toxic endogenous aldehyde, induces neurofilament-l aggregation. BMB Rep. 2008, 41(9):635-639.
19. Jinsmaa Y., Florang V.R., Rees J.N., Anderson D.G., Strack S., Doorn J.A. Products of oxidative stress inhibit aldehyde oxidation and reduction pathways in dopamine catabolism yielding elevated levels of a reactive intermediate. Chem. Res. Toxicol. 2009, 22(5):835-841.
20. Khatua S., Choi S.H., Lee J., Huh J.O., Do Y., Churchill D.G. Highly selective fluorescence detection of Cu2+ in water by chiral dimeric Zn2+ complexes through direct displacement. Inorg. Chem. 2009, 48(5):1799.
21. Khatua S., Choi S.H., Lee J., Kim K., Do Y., Churchill D.G. Aqueous fluorometric and colorimetric sensing of phosphate ions by a fluorescent dinuclear zinc complex. Inorg. Chem. 2009, 48(7):2993-2999.
22. Korytar P., Molnarova M., Sivonova M., Zitnanova I., Ulicna O., Liptakova A., Carsky J., Durackova Z. Effects of aminoguanidine Schiff's base on biomarkers of the oxidative stress, 4-hydroxy-2-nonenal and conjugated dienes, in the model diabetes mellitus. Gen. Physiol. Biophys. 2002, 21(3):337-344.
23. Koschier E.H., Hoffmann D., Riefler J. Influence of salicylaldehyde and methyl salicylate on post-landing behaviour of Frankliniella occidentalis Pergande. J. Appl. Entomol. 2007, 131(5):362-367.
24. Kowalik-Jankowska T., Rajewska A., Jankowska E., Wisniewska K., Grzonka Z. Products of Cu(II)-catalyzed oxidation of the N-terminal fragments of alpha-synuclein in the presence of hydrogen peroxide. J. Inorg. Biochem. 2006, 100(10):1623-1631.
25. Kowalik-Jankowska T., Rajewska A., Wisniewska K., Grzonka Z., Jezierska J. Coordination abilities of N-terminal fragments of alpha-synuclein towards copper(II) ions: a combined potentiometric and spectroscopic study. J. Inorg. Biochem. 2005, 99(12):2282-2291.
26. Kozlowski H., Janicka-Klos A., Brasun J., Gaggelli E., Valensin D., Valensin G. Copper, iron, and zinc ions homeostasis and their role in neurodegenerative disorders (metal uptake, transport, distribution and regulation). Coord. Chem. Rev. 2009, 253(21-22):2665-2685.
27. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 2001, 46(1-3):3-26.
28. Long E.K., Murphy T.C., Leiphon L.J., Watt J., Morrow J.D., Milne G.L., Howard J.R.H., Picklo M.J. Trans-4-hydroxy-2-hexenal is a neurotoxic product of docosahexaenoic (22: 6; n-3) acid oxidation. J. Neurochem. 2008, 105(3):714-724.
29. Lucas H.R., Lee J.C. Effect of dioxygen on copper(II) binding to [alpha]-synuclein. J. Inorg. Biochem. 2009, 104(3):245-249.
30. McLean P.J., Kawamata H., Ribich S., Hyman B.T. Membrane association and protein conformation of α-synuclein in intact neurons. J. Biol. Chem. 2000, 275(12):8812-8816.
31. Nasstrom T., Wahlberg T., Karlsson M., Nikolajeff F., Lannfelt L., Ingelsson M., Bergstrom J. The lipid peroxidation metabolite 4-oxo-2-nonenal cross-links alpha-synuclein causing rapid formation of stable oligomers. Biochem. Biophys. Res. Commun. 2009, 378(4):872-876.
32. Nilsson B.O. Biological effects of aminoguanidine: an update. Inflamm. Res. 1999, 48(10):509-515.
33. Pardridge W.M. Transport of small molecules through the blood-brain-barrier-biology and methodology. Adv. Drug Deliv. Rev. 1995, 15(1-3):5-36.
34. Pardridge W.M. CNS drug design based on principles of blood-brain barrier transport. J. Neurochem. 1998, 70(5):1781-1792.
35. Peng Y., Wang C.S., Xu H.H., Liu Y.N., Zhou F.M. Binding of alpha-synuclein with Fe(III) and with Fe(II) and biological implications of the resultant complexes. J. Inorg. Biochem. 2010, 104(4):365-370.
36. Prudent R., López-Ramos M., Moucadel V., Barette C., Grierson D., Mouawad L., Florent J.-C., Lafanechère L., Schmidt F., Cochet C. Salicylaldehyde derivatives as new protein kinase CK2 inhibitors. Biochim. Biophys. Acta 2008, 1780:1412-1420.
37. Qin Z., Hu D., Han S., Reaney S.H., Monte D.A.D., Fink A.L. Effect of 4-hydroxy-2-nonenal modification on A-synuclein aggregation. J. Biol. Chem. 2007, 282(8):5862-5870.
38. Radulovic N., Misic M., Aleksic J., Dokovi D., Palic R., Stojanovic G. Antimicrobial synergism and antagonism of salicylaldehyde in Filipendula vulgaris essential oil. Fitoterapia 2007, 78(7-8):565-570.
39. Rees J.N., Florang V.R., Eckert L.L., Doorn J.A. Protein reactivity of 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite, is dependent on both the aldehyde and the catechol. Chem. Res. Toxicol. 2009, 22:1256-1263.
40. Russom C.L., Bradbury S.P., Broderius S.J., Hammermeister D.E., Drummond R.A. Predicting modes of toxic action from chemical structure: acute toxicity in the fathead minnow (Pimephales promelas). Environ. Toxicol. Chem. 1997, 16(5):948-967.
41. Sasaki N.A., Garcia-Alvarez M.C., Wang Q., Ermolenko L., Franck G., Nhiri N., Martin M.T., Audic N., Potier P. N-terminal 2,3-diaminopropionic acid (Dap) peptides as efficient methylglyoxal scavengers to inhibit advanced glycation endproduct (AGE) formation. Bioorg. Med. Chem. 2009, 17(6):2310-2320.
42. Shamoto-Nagai M., Maruyama W., Hashizume Y., Yoshida M., Osawa T., Riederer P., Naoi M. In parkinsonian substantia nigra, A-synuclein is modified by acrolein, a lipid-peroxidation product, and accumulates in the dopamine neurons with inhibition of proteasome activity. J. Neural Transm. 2007, 114:1559-1567.
43. Smith W.W., Margolis R.L., Li X.J., Troncoso J.C., Lee M.K., Dawson V.L., Dawson T.M., Iwatsubo T., Ross C.A. Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. J. Neurosci. 2005, 25(23):5544-5552.
44. Souza J.M., Giasson B.I., Chen Q.P., Lee V.M.Y., Ischiropoulos H. Dityrosine cross-linking promotes formation of stable alpha-synuclein polymers-implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J. Biol. Chem. 2000, 275(24):18344-18349.
45. Spillantini M.G., Crowther R.A., Jakes R., Hasegawa M., Goedert M. Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. U.S.A. 1998, 95(11):6469-6473.
46. Tofaris G.K., Razzaq A., Ghetti B., Lilley K.S., Spillantini M.G. Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J. Biol. Chem. 2003, 278(45):44405-44411.
47. Uversky V.N. Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation. J. Neurochem. 2007, 103(1):17-37.
48. VanderJagt D.L., Hunsaker L.A., VanderJagt T.J., Gomez M.S., Gonzales D.M., Deck L.M., Royer R.E. Inactivation of glutathione reductase by 4-hydroxynonenal and other endogenous aldehydes. Biochem. Pharmacol. 1997, 53(8):1133-1140.
49. Wang X., Dong Y., Xu S., Wang L., Han S. Quantitative structure-activity relationships for the toxicity to the tadpole Rana japonica of selected phenols. Bull. Environ. Contam. Toxicol. 2000, 64(6):859-865.